Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback